REN and Hyperkalemia: In clinical practice, the up-titration of foundational GDMT, particularly renin–angiotensin system inhibitors and MRAs, is often hindered by concerns about drug-related worsening renal function and hyperkalemia, particularly in high-risk patients [18,19].